Stockreport

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

Prelude Therapeutics Incorporated  (PRLD) 
PDF WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage preci [Read more]